XML 89 R81.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Disclosure of Operating Segment Information (Detail) - AUD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Revenue      
License revenue $ 0 $ 0 $ 0
Other income      
Research material sales 59,709 119,089 191,721
Grant income 4,974,823 3,722,788 3,314,001
Net gain on fair value movement of warrants 0 0 131,896
Net gain on foreign exchange 0 113,458 623,511
Interest income 5,287,209 3,882,757 938,999
Total revenue and other income 10,331,373 7,838,092 5,200,128
Miscellaneous income 390    
Net change on fair value movement 9,242 0 0
Segment Result (61,434,165) (42,716,625) (39,896,348)
Profit/(loss) before income tax expense (61,434,165) (42,716,625) (39,896,348)
Income tax expense 0 0 0
Loss after income tax expense (61,434,165) (42,716,625) (39,896,348)
Total segment assets 156,983,434 201,579,281 147,448,990
Total segment liabilities 13,348,071 12,057,539 10,979,601
Immunotherapy [Member]      
Revenue      
License revenue 0 0 0
Other income      
Research material sales 59,709 119,089 191,721
Grant income 4,974,823 3,722,788 3,314,001
Total revenue and other income 5,034,532 3,841,877 3,505,722
Segment Result (65,020,504) (46,556,929) (41,431,305)
Profit/(loss) before income tax expense (65,020,504) (46,556,929) (41,431,305)
Income tax expense 0   0
Total segment assets 156,983,434 201,579,281 147,448,990
Total segment liabilities 13,348,071 12,057,539 10,979,601
Unallocated [member]      
Revenue      
License revenue 0   0
Other income      
Net gain on fair value movement of warrants   0 131,896
Net gain on foreign exchange   113,458 623,511
Interest income 5,287,209 3,882,757 938,999
Total revenue and other income 5,296,841 3,996,215 1,694,406
Miscellaneous income 390    
Net change on fair value movement 9,242    
Segment Result 3,586,339 3,840,304 1,534,957
Profit/(loss) before income tax expense 3,586,339 $ 3,840,304 1,534,957
Income tax expense $ 0   $ 0